Mosanna Therapeutics

Mosanna Therapeutics is a clinical-stage biotech company developing an easy-to-use nighttime nasal spray, MOS118, to treat obstructive sleep apnea (OSA). Their approach focuses on restoring the body's natural airway control during sleep, offering a drug-based alternative to traditional mechanical treatments.

Funding Round: Series A

Funding Amount: $80M

Date: 09-Jun-2025

Investors: Pivotal bioVenture Partners, EQT Life Sciences, Forbion, Broadview Ventures, Norwest, Forty51 Ventures, Supermoon Capital, High-Tech Gründerfonds (HTGF)

Markets: Biotech, Healthtech

HQ: Redwood City, California, United States

Founded: 2022

Website: https://mosanna.com/

LinkedIn: https://www.linkedin.com/company/mosanna-therapeutics/

Twitter:

Instagram:

Facebook:

Crunchbase: https://www.crunchbase.com/organization/mosanna-therapeutics

Pitchbook: https://pitchbook.com/profiles/company/501454-54